Recursion is Granted FDA Fast Track Designation for REC-2282 for

RXRX: Recursion Pharmaceuticals, Inc.
2021-10-07 07:55:00
Recursion is Granted FDA Fast Track Designation for REC-2282 for the Potential Treatment of NF2-Mutated Meningiomas